FDA Approves First Drug for HER2 Lung Cancer FDA Approves First Drug for HER2 Lung Cancer

The agency has granted an accelerated approval for trastuzumab deruxtecan (Enhertu) to be used in patients with metastatic non –small cell lung cancer whose tumors have HER2 mutations.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news